Pulmonx Corporation
Pulmonx Corporation (LUNG) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · LUNG · as of Jun 9, 2026
Key Statistics
Explore Pulmonx Corporation Data
lung stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 44.4%
The LUNG analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $10.00, representing +571.14% upside from the current price of $1.49.
Competitors & Peers
lung competitorsLUNG
ACRV
ASRT
EDAP
HYPR
IMUXStock Performance
Full HistoryAbout Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offerin…
what is pulmonx corporation · lung stock overview · pulmonx corporation company profile · who is pulmonx corporation ceo · lung NASDAQ · pulmonx corporation headquarters · pulmonx corporation business segments
About Stock Overview & Key Data
Pulmonx Corporation (LUNG) is a Healthcare company in the Medical - Devices industry, listed on NASDAQ since Oct 1, 2020. As of the latest trading session, LUNG stock price is $1.49, with a market capitalization of $62.9M. The stock has returned -56.18% over the past 12 months and -32.58% year-to-date.
According to 9 Wall Street analysts, the consensus rating for Pulmonx Corporation stock is Buy, with an average 12-month price target of $10.00. In fiscal year 2025, Pulmonx Corporation reported revenue of $90.5M and net income of -$54.0M. For detailed data — including Pulmonx Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Pulmonx Corporation (LUNG) stock price is $1.49. The stock is traded on NASDAQ under the ticker symbol LUNG. The 52-week range is $1.13 – $3.88.